Primary failure of bortezomib in newly diagnosed multiple myeloma – understanding the magnitude, predictors, and significance

Overcoming bortezomib resistance in multiple myeloma

(2014) Megan Y. Murray et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation

(2014) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

(2014) Lotfi Benboubker et al.   NEW ENGLAND JOURNAL OF MEDICINE

International Myeloma Working Group recommendations for global myeloma care

(2013) H Ludwig et al.   LEUKEMIA

IMWG consensus on risk stratification in multiple myeloma

(2013) W J Chng et al.   LEUKEMIA

Cytogenetic and clinical risk factors for assessment of ultra high-risk multiple myeloma

(2013) Junling Zhuang et al.   LEUKEMIA RESEARCH

Proteasome inhibitors in multiple myeloma: 10 years later

(2012) P. Moreau et al.   BLOOD

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

(2012) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

(2011) P. Moreau et al.   BLOOD

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

(2011) M. Cavo et al.   BLOOD

Modern Therapy of Acute Lymphoblastic Leukemia

(2011) Renato Bassan et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial

(2010) Jean-Luc Harousseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

(2010) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial

(2009) C B Reeder et al.   LEUKEMIA

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE